RANCHO CUCAMONGA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- iPower Inc. (Nasdaq: IPW) (“iPower” or the “Company”) today announced that it has eliminated a major operating cost center while receiving total consideration of approximately $2.3 million as part of a strategic restructuring designed to streamline operations and strengthen the Company’s core supply chain and fulfillment platform. Through this transaction, iPower has removed major costs associated with online sales operations by selling its subsidi ...

Core Insights - Geron Corporation has announced a strategic restructuring plan aimed at long-term value creation for patients and shareholders while improving financial discipline [2][3] - The restructuring is expected to lead to a one-third reduction in the current workforce of approximately 260 employees, with significant savings anticipated in operating expenses for 2026 [3] Group 1: Restructuring Plan - The restructuring plan is designed to streamline the organizational structure and advance the company's strategy [3] - Initial projected full year 2026 operating expenses are expected to be lower than those projected for 2025, with savings beginning in the first quarter of 2026 [3] - The restructuring will incur cash-based expenses, with further details to be provided in a Current Report on Form 8-K [3] Group 2: Business Focus - The company remains focused on driving the commercial growth of RYTELO in the U.S. and exploring opportunities for its availability outside the U.S. [3] - Geron is continuing to advance its Phase 3 IMpactMF trial, which is critical for the development of its lead product, RYTELO [3][4] - RYTELO (imetelstat) is a first-in-class telomerase inhibitor approved for treating certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) [4]

Core Insights - Proactive provides fast, accessible, and actionable business and finance news content to a global investment audience [2] - The company focuses on medium and small-cap markets while also covering blue-chip companies and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, mining, oil and gas, and emerging technologies [3] Technology Adoption - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Insights - TME Pharma has undergone a reorganization to a lower-cost outsourced staffing model, which is expected to lead to significant cost reductions starting in the second half of 2025 [2][3] - The company raised €1.7 million through a bond issuance in May 2025 and an additional €500,000 in August 2025, indicating investor confidence in the new strategy [2] - TME Pharma is committed to continuing the research and development of its lead assets, NOX A12 and NOX E36, while also exploring investments in potentially profitable businesses [3][11] Financial Performance - In the first half of 2025, TME Pharma recorded a turnover of €27,000 compared to €0 in the same period of 2024, with a net loss of €2.1 million, an improvement from a loss of €3.2 million in H1 2024 [4] - The cash position as of June 30, 2025, was €2.06 million, down from €2.70 million on June 30, 2024, with negative equity of €570,000 [4] - Financial visibility extends to May 28, 2026, with the potential to negotiate an extension of maturing debt to improve financial stability [4] Leadership and Strategy - Diede van den Ouden was appointed as the new CEO in June 2025, and he emphasizes a collaborative transition with the previous leadership [5] - The company is focusing on a strategic restructuring to unlock the value of its lead assets, NOX-A12 and NOX-E36, while also exploring acquisitions and partnerships in stable, profitable businesses [7][11] - TME Pharma aims to create a fundamentally profitable corporate structure where revenues from non-core activities will support the development of its patented drug candidates [11] Research and Development - NOX-A12 is currently in a Phase 1/2 clinical trial for glioblastoma, with FDA Fast Track Designation and orphan drug designation in the US and Europe [6][8] - NOX-E36 is being evaluated for ophthalmic diseases, focusing on well-tolerated therapies with anti-fibrotic effects [6] - The company is also planning a Phase 2 study for NOX-A12 in combination with other treatments for metastatic pancreatic cancer [9]

Group 1 - AGM Group Holdings Inc. (AGMH) experienced a significant after-hours trading surge of 158.74%, rising to $5.77 from a closing price of $2.23 on Thursday, following the filing of Form 6-K with the SEC [1][5] - The filing disclosed the completion of the sale of AGM's Hong Kong subsidiary, Nanjing Lucun Semiconductor Co. Ltd., to Hong Kong Giant Electronics Co., Limited for $57.45 million on May 7, with Nanjing Lucun primarily engaged in manufacturing advanced hardware and computing equipment [2] - Investors perceive the asset sale as transformational, providing cash proceeds exceeding 13 times AGM's current market capitalization, with unaudited pro forma financial statements indicating continuing operations generated $3.41 million in net income for 2024, alongside revenues of $32.04 million [3] Group 2 - The sale represents a significant transaction for AGM, which has a market value of $4.29 million and a price-to-earnings ratio of 0.32, with the stock showing high volatility, fluctuating between $1.09 and $108.48 over the past year [4] - AGM's stock has seen a dramatic decline of 97.05% for 2025, with a year-to-date peak of $75.50 on December 31, and a closing price of $2.23 yesterday, marking a 97.03% decline from the peak [4] - During regular trading hours, AGMH closed down 5.91% before the after-hours reversal, indicating short-term upward movement according to Benzinga's Edge Stock Rankings [5]

Core Viewpoint - Golden Triangle Ventures, Inc. (GTVH) has executed a binding Memorandum of Understanding (MOU) that signifies a new leadership direction, high-growth assets, and a long-term strategic vision for the company [1][2]. Group 1: Strategic Developments - The MOU will enable GTVH to integrate a portfolio of fast-moving consumer brands and a distribution company with over $20 million in annual revenue, aimed at unlocking shareholder value and enhancing operational efficiency [2][5]. - Javier Leal has been appointed to lead the company, bringing a strong track record in building businesses and merging his portfolio into GTVH [3][7]. - The outgoing CEO, Steffan Dalsgaard, will transition to an advisory role for 60 days to ensure a smooth handover and the successful spin-off of Lavish Entertainment [4][7]. Group 2: Financial and Operational Focus - GTVH's noteholder has committed funding for acquiring a new publicly traded company that will include Lavish Entertainment and Destino Ranch, with existing shareholders set to receive an equity dividend in the new entity [5][6]. - The company plans to spin out LE Logistics and non-performing legacy assets to concentrate on high-growth opportunities, thereby streamlining operations and focusing on profitability [6][7]. Group 3: Future Outlook - The restructuring is described as a relaunch, with the potential for two powerful narratives unfolding simultaneously for shareholders [7]. - Additional details regarding leadership changes and dividend instructions are expected to be released in the coming weeks [7].